Limits...
Effect of hydroxyapatite on the physicochemical characteristics of a gentamicin-loaded monoolein gel intended to treat chronic osteomyelitis.

Semdé R, Gondi RF, Sombié BC, Yaméogo BG, Ouédraogo M - J Adv Pharm Technol Res (2012)

Bottom Line: Many works have demonstrated the real potential of gentamicin-monoolein-water formulations as bioresorbable and sustained-release implants for the local treatment of the chronic osteomyelitis.The rheological, thermal (differential scanning calorimetric and thermogravimetric diffraction analysis), X-ray diffraction, and dissolution studies have showed that the presence of hydroxyapatite does not dramatically disturb the cubic liquid crystalline structure of the monoolein-water gel and their ability to progressively release the antibiotic.Implant 20% that was capable to release gentamicin sulfate over a period of four weeks without marked burst effect could be used as a more suitable biodegradable delivery system for the local management of chronic osteomyelitis.

View Article: PubMed Central - PubMed

Affiliation: Department of Applied Pharmaceutical Sciences, UFR/SDSS, University of Ouagadougou, 03 BP 7021 Ouagadougou 03, Burkina Faso, West Africa.

ABSTRACT
Many works have demonstrated the real potential of gentamicin-monoolein-water formulations as bioresorbable and sustained-release implants for the local treatment of the chronic osteomyelitis. In order to improve the efficacy of this type of implant, the incorporation of hydroxyapatite, a well-known osteointegrator material, is thought to be an interesting approach. Five formulations incorporating 0, 2.5, 5, 10, and 20% of hydroxyapatite were examined with regard to their physicochemical and in vitro drug release characteristics. The rheological, thermal (differential scanning calorimetric and thermogravimetric diffraction analysis), X-ray diffraction, and dissolution studies have showed that the presence of hydroxyapatite does not dramatically disturb the cubic liquid crystalline structure of the monoolein-water gel and their ability to progressively release the antibiotic. Implant 20% that was capable to release gentamicin sulfate over a period of four weeks without marked burst effect could be used as a more suitable biodegradable delivery system for the local management of chronic osteomyelitis.

No MeSH data available.


Related in: MedlinePlus

In vitro release profiles of gentamicin sulfate from Implants 0%, 2.5%, 5%, 10%, and 20%
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3401670&req=5

Figure 4: In vitro release profiles of gentamicin sulfate from Implants 0%, 2.5%, 5%, 10%, and 20%

Mentions: The release of gentamicin sulfate from all the implants was progressive and sustained [Figure 4], as already observed from various monoolein-water crystalline cubic phase gels.[22324] It also depended on the hydroxyapatite content of the implants. It was higher than 50% and 60 % after seven days (168 hours) and 20 days (480 hours), respectively. The drug release from Implant 0 was faster than that from implants with hydroxyapatite. For these ones, however, lower the hydroxyapatite content, slower is the gentamicin sulfate release.


Effect of hydroxyapatite on the physicochemical characteristics of a gentamicin-loaded monoolein gel intended to treat chronic osteomyelitis.

Semdé R, Gondi RF, Sombié BC, Yaméogo BG, Ouédraogo M - J Adv Pharm Technol Res (2012)

In vitro release profiles of gentamicin sulfate from Implants 0%, 2.5%, 5%, 10%, and 20%
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3401670&req=5

Figure 4: In vitro release profiles of gentamicin sulfate from Implants 0%, 2.5%, 5%, 10%, and 20%
Mentions: The release of gentamicin sulfate from all the implants was progressive and sustained [Figure 4], as already observed from various monoolein-water crystalline cubic phase gels.[22324] It also depended on the hydroxyapatite content of the implants. It was higher than 50% and 60 % after seven days (168 hours) and 20 days (480 hours), respectively. The drug release from Implant 0 was faster than that from implants with hydroxyapatite. For these ones, however, lower the hydroxyapatite content, slower is the gentamicin sulfate release.

Bottom Line: Many works have demonstrated the real potential of gentamicin-monoolein-water formulations as bioresorbable and sustained-release implants for the local treatment of the chronic osteomyelitis.The rheological, thermal (differential scanning calorimetric and thermogravimetric diffraction analysis), X-ray diffraction, and dissolution studies have showed that the presence of hydroxyapatite does not dramatically disturb the cubic liquid crystalline structure of the monoolein-water gel and their ability to progressively release the antibiotic.Implant 20% that was capable to release gentamicin sulfate over a period of four weeks without marked burst effect could be used as a more suitable biodegradable delivery system for the local management of chronic osteomyelitis.

View Article: PubMed Central - PubMed

Affiliation: Department of Applied Pharmaceutical Sciences, UFR/SDSS, University of Ouagadougou, 03 BP 7021 Ouagadougou 03, Burkina Faso, West Africa.

ABSTRACT
Many works have demonstrated the real potential of gentamicin-monoolein-water formulations as bioresorbable and sustained-release implants for the local treatment of the chronic osteomyelitis. In order to improve the efficacy of this type of implant, the incorporation of hydroxyapatite, a well-known osteointegrator material, is thought to be an interesting approach. Five formulations incorporating 0, 2.5, 5, 10, and 20% of hydroxyapatite were examined with regard to their physicochemical and in vitro drug release characteristics. The rheological, thermal (differential scanning calorimetric and thermogravimetric diffraction analysis), X-ray diffraction, and dissolution studies have showed that the presence of hydroxyapatite does not dramatically disturb the cubic liquid crystalline structure of the monoolein-water gel and their ability to progressively release the antibiotic. Implant 20% that was capable to release gentamicin sulfate over a period of four weeks without marked burst effect could be used as a more suitable biodegradable delivery system for the local management of chronic osteomyelitis.

No MeSH data available.


Related in: MedlinePlus